Table of Contents Author Guidelines Submit a Manuscript
TheScientificWorldJOURNAL
Volume 11, Pages 1699-1711
http://dx.doi.org/10.1100/2011/752790
Clinical Study

Pro- and Antiapoptotic Markers in Upper Tract Urothelial Carcinoma Associated with Balkan Endemic Nephropathy

1Institute of Pathology, Faculty of Medicine, University of Nis, 18000 Nis, Serbia
2Department of Pathology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2121, Japan
3Public Health Institute, Nis, Serbia
4Institute of Nephrology, Faculty of Medicine, University of Nis, Boulevard Dr Zoran Djindjic 81, 18000 Nis, Serbia

Received 4 July 2011; Accepted 6 September 2011

Academic Editor: Anthony Atala

Copyright © 2011 Ljubinka Jankovic-Velickovic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Polenakovic and V. Stefanovic, “Balkan nephropathy.,” in Oxford Textbook of Clinical Nephrology, J. S. Cameron, A. M. Davison, J. P. Grunfeld, D. Kerr, and E. Ritz, Eds., pp. 857–866, Oxford University Press, Oxford, UK, 1992. View at Google Scholar
  2. V. Stefanović and M. Polenaković, “Fifty years of research in balkan endemic nephropathy: where are we now?” Nephron, vol. 112, no. 2, pp. c51–c55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Toncheva, T. Dimitrov, and S. Stojanova, “Etiology of Balkan endemic nephropathy: a multifactorial disease?” European Journal of Epidemiology, vol. 14, no. 4, pp. 389–394, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Stefanovic, D. Toncheva, S. Atanasova, and M. Polenakovic, “Etiology of balkan endemic nephropathy and associated urothelial cancer,” American Journal of Nephrology, vol. 26, no. 1, pp. 1–11, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Ivić, “Etiology of endemic nephropathy,” Lijecnicki Vjesnik, vol. 91, no. 12, pp. 1273–1281, 1969. View at Google Scholar · View at Scopus
  6. J. P. Cosyns, M. Jadoul, J. P. Squifflet, J. F. De Plaen, D. Ferluga, and C. Van Ypersele De Strihou, “Chinese herbs nephropathy: a clue to Balkan endemic nephropathy?” Kidney International, vol. 45, no. 6, pp. 1680–1688, 1994. View at Google Scholar · View at Scopus
  7. T. Petkova-Bocharova and M. Castegnaro, “Ochratoxin A contamination of cereals in an area of high incidence of Balkan endemic nephropathy in Bulgaria,” Food Additives and Contaminants, vol. 2, no. 4, pp. 267–270, 1985. View at Google Scholar · View at Scopus
  8. G. L. Feder, Z. Radovanovic, and R. B. Finkelman, “Relationship between weathered coal deposits and the etiology of Balkan endemic nephropathy,” Kidney International Supplements, vol. 40, no. 34, pp. S-9–S-11, 1991. View at Google Scholar · View at Scopus
  9. S. D. Petkovic, “Epidemiology and treatment of renal pelvic and ureteral tumors,” Journal of Urology, vol. 114, no. 6, pp. 856–865, 1975. View at Google Scholar · View at Scopus
  10. V. Stefanovic and Z. Radovanovic, “Balkan endemic nephropathy and associated urothelial cancer,” Nature Clinical Practice Urology, vol. 5, no. 2, pp. 105–112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. E. Krasteva and E. I. Georgieva, “Germline p53 single-base changes associated with Balkan endemic nephropathy,” Biochemical and Biophysical Research Communications, vol. 342, no. 2, pp. 562–567, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. P. Grollman, S. Shibutani, M. Moriya et al., “Aristolochic acid and the etiology of endemic (Balkan) nephropathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 29, pp. 12129–12134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. L. J. Velickovic, T. Hattori, and V. Stefanovic, “Molecular markers in upper urothelial carcinoma associated to Balkan endemic nephropathy. Aristolochic acid as the major risk factor of the worldwide disease,” TheScientificWorldJournal, vol. 9, pp. 1360–1373, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. J. McKnight, S. B. Gray, H. F. O'Kane, S. R. Johnston, and K. E. Williamson, “Apoptosis and chemotherapy for bladder cancer,” Journal of Urology, vol. 173, no. 3, pp. 683–690, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. J. A. Karam, Y. Lotan, P. I. Karakiewicz et al., “Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy,” Lancet Oncology, vol. 8, no. 2, pp. 128–136, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Lopez-Beltran, G. Sauter, and T. Gasser, “Tumors of the urinary system. Infiltrating urothelial carcinoma,” in World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Urinary System and Male Genital Organs, J. N. Eble, G. Sauter, J. I. Epstein, and I. A. Sesterhenn, Eds., pp. 93–109, IARC, Lyon, France, 2004. View at Google Scholar
  17. L. H. Sobin and C. Wittekind, Eds., TNM Classification of Malignant Tumors, John Wiley & Son, New York, NY, USA, 6th edition, 2002.
  18. E. M. Genega, M. Kapali, M. Torres-Quinones et al., “Impact of the 1998 World Health Organization/International Society of Urological Pathology classification system for urothelial neoplasms of the kidney,” Modern Pathology, vol. 18, no. 1, pp. 11–18, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Giannopoulou, L. Nakopoulou, A. Zervas et al., “Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications,” Urological Research, vol. 30, no. 5, pp. 342–345, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Yin, N. Chen, Y. Zhang et al., “Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder,” Modern Pathology, vol. 19, no. 11, pp. 1487–1497, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. R. P. Singh, A. Tyagi, G. Sharma, S. Mohan, and R. Agarwal, “Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin,” Clinical Cancer Research, vol. 14, no. 1, pp. 300–308, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Bressenot, S. Marchal, L. Bezdetnaya, J. Garrier, F. Guillemin, and F. Plénat, “Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma,” Journal of Histochemistry and Cytochemistry, vol. 57, no. 4, pp. 289–300, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Colin, P. Koenig, A. Ouzzane et al., “Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract,” BJU International, vol. 104, no. 10, pp. 1436–1440, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. W. F. Catto, D. R. Yates, I. Rehman et al., “Behavior of urothelial carcinoma with respect to anatomical location,” Journal of Urology, vol. 177, no. 5, pp. 1715–1720, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Eltz, E. Comperat, O. Cussenot, and M. Rouprêt, “Molecular and histological markers in urothelial carcinomas of the upper urinary tract,” BJU International, vol. 102, no. 5, pp. 532–535, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. F. D. Debelle, J. L. Vanherweghem, and J. L. Nortier, “Aristolochic acid nephropathy: a worldwide problem,” Kidney International, vol. 74, no. 2, pp. 158–169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Stefanovic, R. Cukuranovic, S. Miljkovic, D. Marinkovic, and D. Toncheva, “Fifty years of balkan endemic nephropathy: challenges of study using epidemiological method,” Renal Failure, vol. 31, no. 5, pp. 409–418, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Jankovic Velickovic, T. Hattori, Z. Dolicanin et al., “Upper urothelial carcinoma in Balkan endemic nephropathy and non-endemic regions: a comparative study of pathological features,” Pathology Research and Practice, vol. 205, no. 2, pp. 89–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. L. J. Velickovic, T. Hattori, M. Visnjic, I. Dimov, M. Stojanovic, and V. Stefanovic, “E-cadherin expression in upper urothelial carcinoma in Balkan Endemic Nephropathy and non-endemic regions,” Pathology Research and Practice, vol. 205, no. 10, pp. 682–689, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Nouraee, S. J. Mowla, A. Ozhand, M. Parvin, S. A. M. Ziaee, and N. Hatefi, “Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker,” Urology Journal, vol. 6, no. 2, pp. 101–108, 2009. View at Google Scholar · View at Scopus
  31. K. Tanaka, S. Iwamoto, G. Gon, T. Nohara, M. Iwamoto, and N. Tanigawa, “Expression of survivin and its relationship to loss of apoptosis in breast carcinomas,” Clinical Cancer Research, vol. 6, no. 1, pp. 127–134, 2000. View at Google Scholar · View at Scopus
  32. O. Moussa, H. Abol-Enein, N. K. Bissada, T. Keane, M. A. Ghoneim, and D. K. Watson, “Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer,” Journal of Urology, vol. 175, no. 6, pp. 2312–2316, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. A. C. Fields, G. Cotsonis, D. Sexton, R. Santoianni, and C. Cohen, “Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome,” Modern Pathology, vol. 17, no. 11, pp. 1378–1385, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. S. F. Shariat, R. Ashfaq, P. I. Karakiewicz, O. Saeedi, A. I. Sagalowsky, and Y. Lotan, “Survivin expression is associated with bladder cancer presence, stage, progression, and mortality,” Cancer, vol. 109, no. 6, pp. 1106–1113, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Skagias, E. Politi, A. Karameris et al., “Survivin expression as a strong indicator of recurrence in urothelial bladder cancer. Predictive value of nuclear versus cytoplasmic staining,” Anticancer Research, vol. 29, no. 10, pp. 4163–4167, 2009. View at Google Scholar · View at Scopus
  36. I. G. Jeong, S. H. Kim, H. G. Jeon et al., “Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract,” Human Pathology, vol. 40, no. 5, pp. 668–677, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Nakanishi, S. Tominaga, S. Hiroi et al., “Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract,” Virchows Archiv, vol. 441, no. 6, pp. 559–563, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. B. Chen, J. J. Tu, J. Kao, X. K. Zhou, and Y. T. Chen, “Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma,” Archives of Pathology and Laboratory Medicine, vol. 132, no. 2, pp. 224–231, 2008. View at Google Scholar · View at Scopus
  39. H. S. Kadhim, A. S. Abdulamir, R. R. Hafidh, F. Abubaker, and K. A. Abbas, “Investigations in the molecular events of transitional cell carcinoma of the bladder,” American Journal of Biochemistry and Biotechnology, vol. 4, no. 4, pp. 408–415, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Karamitopoulou, C. A. Rentsch, R. Markwalder, C. Vallan, G. N. Thalmann, and T. Brunner, “Prognostic significance of apoptotic cell death in bladder cancer: a tissue microarray study on 179 urothelial carcinomas from cystectomy specimens,” Pathology, vol. 42, no. 1, pp. 37–42, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Nakanishi, S. Tominaga, T. Kawai, C. Torikata, T. Aurues, and T. Ikeda, “Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract,” Virchows Archiv, vol. 432, no. 5, pp. 445–450, 1998. View at Publisher · View at Google Scholar · View at Scopus
  42. J. C. Reed, “Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities,” Cell Death and Differentiation, vol. 13, no. 8, pp. 1378–1386, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. J. F. Curtin and T. G. Cotter, “Live and let die: regulatory mechanisms in Fas-mediated apoptosis,” Cellular Signalling, vol. 15, no. 11, pp. 983–992, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Yamana, V. Bilim, N. Hara et al., “Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression,” British Journal of Cancer, vol. 93, no. 5, pp. 544–551, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. A. M. Gown and M. C. Willingham, “Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3,” Journal of Histochemistry and Cytochemistry, vol. 50, no. 4, pp. 449–454, 2002. View at Google Scholar · View at Scopus
  46. J. J. Oudejans, A. Harijadi, S. A. G. M. Cillessen et al., “Absence of caspase 3 activation in neoplastic cells of nasopharyngeal carcinoma biopsies predicts rapid fatal outcome,” Modern Pathology, vol. 18, no. 7, pp. 877–885, 2005. View at Publisher · View at Google Scholar · View at Scopus